Pankaine Spinal Tung: Uses, Dosage & Side Effects
A hyperbaric local anesthetic solution for spinal (intrathecal) anesthesia during surgical procedures on the lower body
Pankaine Spinal Tung is a hyperbaric (heavy) local anesthetic solution containing bupivacaine hydrochloride 5 mg/ml formulated with glucose to produce a solution denser than cerebrospinal fluid. It is used exclusively for spinal (intrathecal) anesthesia to provide regional nerve blockade during surgical procedures involving the lower abdomen, pelvis, perineum, and lower extremities. The hyperbaric formulation allows the anesthesiologist to precisely control the distribution and cephalad level of the nerve block by adjusting the patient's position on the operating table. Bupivacaine, the active substance, is listed on the WHO Model List of Essential Medicines and has been a cornerstone of modern spinal anesthesia for over five decades. This medication must only be administered by or under the direct supervision of experienced anesthesiologists in hospital settings with full resuscitation facilities immediately available.
Quick Facts: Pankaine Spinal Tung
Key Takeaways
- Pankaine Spinal Tung is a hyperbaric local anesthetic containing bupivacaine hydrochloride 5 mg/ml, specifically formulated for intrathecal (spinal) injection to provide reliable regional anesthesia for lower body surgical procedures including cesarean section, orthopedic surgery, and urological procedures.
- The hyperbaric (heavy) formulation, achieved by the addition of glucose, gives the solution a specific gravity greater than cerebrospinal fluid, allowing the anesthesiologist to control block spread through patient positioning and producing more predictable anesthesia than isobaric alternatives.
- Onset of sensory block occurs within 1–5 minutes, with surgical anesthesia established in 10–15 minutes; duration of action is typically 1.5–3.5 hours depending on dose, making it suitable for the majority of lower body surgical procedures.
- Bupivacaine is listed on the WHO Model List of Essential Medicines and has over 50 years of established clinical use, with a well-characterized safety and efficacy profile when administered by trained practitioners.
- Pankaine Spinal Tung must only be administered by qualified anesthesiologists in hospital settings with continuous hemodynamic monitoring and full resuscitation equipment immediately available, as serious complications including hypotension, high spinal block, and rare cardiovascular toxicity can occur.
What Is Pankaine Spinal Tung and What Is It Used For?
Pankaine Spinal Tung contains the active substance bupivacaine hydrochloride, an amide-type local anesthetic that has been one of the most widely used agents for spinal anesthesia since its introduction into clinical practice in the 1960s. Bupivacaine belongs to the same chemical family as lidocaine, ropivacaine, and mepivacaine but is distinguished by its prolonged duration of action, high potency, and its particular suitability for spinal (intrathecal) administration. The designation “Spinal Tung” derives from the Nordic pharmaceutical terminology where “tung” translates as “heavy,” indicating that this formulation is denser than normal cerebrospinal fluid (CSF) — a property known as hyperbaricity.
The hyperbaric nature of this formulation is achieved by the addition of glucose (dextrose), typically at a concentration of 80 mg/ml. This gives the solution a specific gravity of approximately 1.026 at 37°C, compared to the specific gravity of CSF which is approximately 1.003–1.009 at the same temperature. This density difference is of critical clinical importance: when the solution is injected into the subarachnoid space, it will sink under the influence of gravity relative to the surrounding CSF. This physical property allows the anesthesiologist to control the distribution and final level of the spinal block by positioning the patient appropriately on the operating table during and immediately after injection — a technique known as gravitational control of block spread that provides far more predictable results than plain (isobaric) formulations.
At the cellular level, bupivacaine works by reversibly blocking voltage-gated sodium channels in the membranes of nerve cells. When injected into the intrathecal space, the drug comes into direct contact with the spinal nerve roots and the surface of the spinal cord. By preventing sodium ions from flowing through nerve cell membranes during depolarization, bupivacaine blocks the generation and propagation of electrical impulses (action potentials) along nerve fibers. This produces a reversible interruption of nerve conduction, affecting sensory (pain, touch, and temperature), motor (muscle movement), and autonomic (blood vessel tone and organ function) nerve pathways. The blockade is concentration-dependent and follows a differential pattern: autonomic fibers (small, unmyelinated) are blocked at the lowest concentrations, followed by sensory fibers, and finally motor fibers (large, myelinated) at the highest concentrations.
Pankaine Spinal Tung is indicated for surgical anesthesia of the lower body when a spinal (subarachnoid) block is appropriate. Common surgical applications include:
- Cesarean section: One of the most common applications worldwide, providing rapid and reliable anesthesia for both elective and urgent cesarean deliveries. Hyperbaric bupivacaine is the preferred agent for obstetric spinal anesthesia in most international and national guidelines, including those of the Obstetric Anaesthetists' Association (OAA) and the Society for Obstetric Anesthesia and Perinatology (SOAP).
- Orthopedic surgery of the lower limbs: Including total hip replacement, total knee replacement, arthroscopic knee surgery, ankle fracture fixation, lower limb amputations, and revision arthroplasty. The duration of action is typically sufficient for most standard orthopedic procedures, and spinal anesthesia has been associated with reduced rates of venous thromboembolism, blood loss, and postoperative confusion compared with general anesthesia in this patient population.
- Urological procedures: Such as transurethral resection of the prostate (TURP), transurethral resection of bladder tumors, cystoscopy, and other lower urinary tract procedures. Spinal anesthesia allows the patient to remain awake, which can be advantageous for detecting early signs of complications such as TURP syndrome or bladder perforation.
- Hernia repair: Inguinal and femoral hernia repairs, where spinal anesthesia provides excellent operating conditions with good muscle relaxation and avoids the risks of airway manipulation in elderly or comorbid patients.
- Lower abdominal surgery: Including appendectomy, lower bowel surgery, and gynecological procedures such as hysterectomy (vaginal or open), and certain laparoscopic procedures with appropriate block levels.
- Perineal and perianal surgery: Such as hemorrhoidectomy, anal fistula repair, and pilonidal sinus excision, where the saddle block technique with hyperbaric bupivacaine provides targeted perineal anesthesia while minimizing cardiovascular effects.
The choice of hyperbaric over isobaric (plain) bupivacaine for spinal anesthesia is an important clinical decision. Multiple randomized controlled trials and systematic reviews have demonstrated that hyperbaric bupivacaine offers several advantages: faster onset of sensory and motor block, more predictable and reliable block levels, better operating conditions, and lower rates of block failure compared with isobaric formulations. A Cochrane systematic review comparing hyperbaric and isobaric spinal bupivacaine found that hyperbaric solutions produced more consistent and predictable spread of anesthesia, supporting their preferred use in clinical practice, particularly for cesarean sections and other procedures requiring a well-defined block level. The evidence base for hyperbaric bupivacaine is among the most robust for any anesthetic drug, with decades of clinical experience across diverse patient populations and surgical settings.
Bupivacaine, the active substance in Pankaine Spinal Tung, is included on the WHO Model List of Essential Medicines, which identifies the most important medications needed in a basic health system. This designation reflects the drug's established efficacy, safety, and importance in global surgical care. Bupivacaine is listed as an essential local anesthetic for both infiltration and spinal anesthesia, underscoring its central role in providing safe surgical anesthesia worldwide, including in resource-limited settings where general anesthesia may be less accessible or carry higher risks.
What Should You Know Before Receiving Pankaine Spinal Tung?
Spinal anesthesia with bupivacaine is a well-established and generally safe procedure when performed by experienced practitioners on appropriately selected patients. However, like all forms of regional anesthesia, it carries specific risks that must be carefully weighed against the benefits for each individual patient. Your anesthesiologist will conduct a thorough pre-anesthetic assessment to determine whether spinal anesthesia with Pankaine Spinal Tung is appropriate for you and to identify any factors that might increase your risk of complications. This assessment typically includes a detailed medical history, physical examination, review of current medications, and review of relevant laboratory tests such as complete blood count, coagulation studies, and, when indicated, imaging studies of the spine.
You should inform your anesthesiologist about all medications you are taking, including prescription drugs, over-the-counter medications, herbal supplements, and recreational substances. It is particularly important to disclose any blood-thinning medications, as these significantly influence the timing and safety of spinal injections. You should also report any previous reactions to local anesthetics, any history of back problems or spinal surgery, any neurological conditions, and any previous difficulties with anesthesia.
Contraindications
Pankaine Spinal Tung must not be used in the following circumstances:
- Known hypersensitivity: Allergy to bupivacaine, any other amide-type local anesthetic (such as lidocaine, ropivacaine, mepivacaine, or prilocaine), or any of the excipients in the formulation. True allergy to amide local anesthetics is extremely rare, and many reported “allergies” on investigation prove to be vasovagal reactions or reactions to preservatives in other formulations.
- Coagulation disorders: Active or clinically significant coagulopathy, thrombocytopenia (platelet count typically below 75–100 × 10&sup9;/L depending on the clinical context), or therapeutic anticoagulation that has not been appropriately discontinued. These conditions significantly increase the risk of spinal hematoma, a rare but potentially devastating complication that can cause permanent paralysis if not diagnosed and surgically treated within hours.
- Infection at the injection site: Skin infection, abscess, cellulitis, or any other source of bacteria at or near the intended lumbar puncture site, as this could introduce microorganisms into the spinal canal and cause meningitis or spinal abscess.
- Systemic sepsis or bacteremia: Active systemic infection carries a theoretical risk of seeding bacteria to the meninges during the puncture, potentially causing meningitis or epidural abscess. The decision to proceed in septic patients requires careful risk-benefit analysis by the anesthetic team.
- Severe hypovolemia or circulatory shock: Patients who are significantly dehydrated, hemorrhaging, or in circulatory shock, as the sympathetic block produced by spinal anesthesia can cause dangerous and sometimes catastrophic cardiovascular collapse in these patients. Resuscitation and stabilization should be achieved before neuraxial anesthesia is considered.
- Raised intracranial pressure: Conditions causing elevated intracranial pressure (such as space-occupying lesions, severe head injury, or obstructive hydrocephalus), as lumbar puncture can precipitate brainstem herniation.
- Severe spinal deformities: Major spinal abnormalities (such as severe scoliosis or previous spinal surgery with hardware) that make lumbar puncture technically impossible or extremely hazardous.
Warnings and Precautions
Several conditions require special caution and careful risk-benefit assessment when considering spinal anesthesia with Pankaine Spinal Tung:
- Cardiovascular disease: Patients with fixed cardiac output states (such as severe aortic stenosis, mitral stenosis, or hypertrophic obstructive cardiomyopathy) may not be able to compensate for the vasodilation and hypotension caused by sympathetic blockade. Patients with significant heart block, unstable arrhythmias, or recent myocardial infarction also require careful evaluation and may benefit from alternative anesthetic techniques.
- Pre-existing neurological disease: Conditions such as multiple sclerosis, peripheral neuropathy, or spinal cord pathology may represent relative contraindications. While evidence suggests that regional anesthesia does not necessarily worsen these conditions, it can be difficult to distinguish between pre-existing deficits and potential complications of the spinal block, so careful documentation before and after the procedure is essential.
- Elderly patients: Older adults are more susceptible to the cardiovascular effects of spinal anesthesia, particularly hypotension, due to reduced cardiovascular reserve and often coexisting atherosclerosis. Lower doses are typically required, and careful fluid management, invasive blood pressure monitoring in higher-risk cases, and preemptive vasopressor support should be planned.
- Anticoagulant and antiplatelet therapy: Patients taking blood-thinning medications require careful timing of the spinal injection relative to their anticoagulant doses. International guidelines from the American Society of Regional Anesthesia (ASRA) and the European Society of Regional Anaesthesia (ESRA) provide specific recommendations for minimum time intervals between anticoagulant administration and neuraxial procedures. These guidelines are updated regularly as new evidence emerges and must be strictly adhered to.
- Hepatic impairment: Bupivacaine is metabolized primarily by the liver via cytochrome P450 enzymes (CYP3A4 and CYP1A2). While systemic absorption from intrathecal injection is minimal, patients with severe hepatic impairment (Child-Pugh class C) may have altered drug handling, particularly if larger doses are required or repeat injections are needed.
- Psychiatric or cognitive issues: Patients who cannot remain still and cooperative during the spinal injection, or who cannot tolerate being awake during surgery even with sedation, may require general anesthesia as an alternative.
The combination of anticoagulant therapy and neuraxial (spinal or epidural) procedures carries a significant risk of spinal hematoma, which can cause permanent paralysis if not promptly diagnosed and surgically evacuated (typically within 6–12 hours of symptom onset). Patients receiving anticoagulants such as warfarin, unfractionated heparin, low-molecular-weight heparins (enoxaparin, dalteparin, tinzaparin), direct oral anticoagulants (rivaroxaban, apixaban, dabigatran, edoxaban), or antiplatelet agents (clopidogrel, prasugrel, ticagrelor) must have their medication carefully managed around the time of the procedure. Specific time intervals between the last dose of anticoagulant and the spinal injection must be observed, as detailed in the ASRA/ESRA guidelines. Always inform your anesthesiologist about ALL blood-thinning medications, including over-the-counter aspirin, supplements such as ginkgo or fish oil, and any recent changes to your medication regimen.
Pregnancy and Breastfeeding
Bupivacaine is one of the most extensively studied drugs in obstetric anesthesia and is widely considered safe for use during pregnancy when administered for spinal anesthesia at standard intrathecal doses. Hyperbaric bupivacaine is the most commonly used agent for spinal anesthesia for cesarean section worldwide, and decades of clinical experience and large-scale observational data support its safety profile in this setting. Maternal and neonatal outcomes are generally excellent when established protocols are followed.
When administered intrathecally, the dose of bupivacaine is very small (typically 10–12.5 mg) and systemic absorption into the maternal circulation is minimal. Although bupivacaine does cross the placenta, fetal drug levels remain low at standard intrathecal doses, and fetal effects are clinically insignificant. Studies of neonatal Apgar scores, umbilical cord blood gases, and neurobehavioral assessments have consistently shown normal outcomes following cesarean delivery under spinal anesthesia with bupivacaine, comparable to or better than general anesthesia. In fact, spinal anesthesia is generally preferred over general anesthesia for cesarean section because it avoids the risks of aspiration, difficult intubation, and neonatal respiratory depression from general anesthetic agents.
Regarding breastfeeding, bupivacaine is excreted into breast milk in very small quantities. Given the small intrathecal dose administered, the low concentrations achieved in maternal plasma, and the very low oral bioavailability of bupivacaine (approximately 6–10%), the amount transferred to the nursing infant is negligible and not expected to cause any adverse effects. Breastfeeding can generally be continued immediately after spinal anesthesia with Pankaine Spinal Tung, and in fact early skin-to-skin contact and breastfeeding initiation after cesarean section is encouraged by international guidelines.
How Does Pankaine Spinal Tung Interact with Other Drugs?
Drug interactions with intrathecal bupivacaine differ in nature and clinical significance from those seen with systemic (intravenous or large-volume local infiltration) administration of local anesthetics. The intrathecal dose of Pankaine Spinal Tung is very small (typically 10–20 mg), and systemic absorption from the subarachnoid space is minimal. Consequently, drug-drug interactions based on shared metabolism or pharmacokinetics are not usually clinically significant. Nevertheless, several important categories of interaction must be considered by the anesthesiologist when planning spinal anesthesia.
The most critical interaction is not a pharmacological drug-drug interaction in the traditional sense, but rather the interaction between anticoagulant or antiplatelet medications and the spinal needle insertion itself. This procedural interaction carries the risk of spinal hematoma, a rare but potentially devastating complication that can lead to permanent paralysis if not promptly diagnosed and surgically evacuated. The risk is dose-dependent and depends on the specific anticoagulant, its pharmacokinetics, and the timing of the last dose relative to the spinal injection.
| Interacting Drug/Class | Type | Effect | Clinical Significance |
|---|---|---|---|
| Anticoagulants (warfarin, heparins, DOACs) | Procedural risk | Increased risk of spinal hematoma | Major – Strict timing guidelines must be followed |
| Antiplatelet agents (clopidogrel, prasugrel, ticagrelor) | Procedural risk | Increased bleeding risk at injection site | Major – Drug-specific washout periods required |
| Other local anesthetics (lidocaine, ropivacaine) | Pharmacodynamic | Additive systemic toxic effects | Moderate – Total local anesthetic dose must be considered |
| Class III antiarrhythmics (amiodarone, sotalol) | Pharmacodynamic | Additive cardiac depressant effects, QT prolongation | Moderate – Monitor cardiac function closely |
| Class Ib antiarrhythmics (mexiletine, tocainide) | Pharmacodynamic | Additive sodium channel blockade | Moderate – Additive central nervous system and cardiac toxicity |
| Antihypertensive medications | Pharmacodynamic | Enhanced hypotension from sympathetic block | Moderate – More aggressive fluid and vasopressor management |
| Beta-blockers | Pharmacodynamic | Blunted compensatory tachycardia; worsened bradycardia | Moderate – Careful heart rate management required |
| Intrathecal opioids (fentanyl, morphine, sufentanil) | Synergistic | Enhanced and prolonged analgesia; possible respiratory depression | Beneficial when managed – Commonly used combination |
| Intrathecal clonidine | Synergistic | Prolonged block duration; increased hypotension and sedation | Beneficial when managed – Used as adjuvant |
| CYP3A4 inhibitors (ketoconazole, ritonavir) | Pharmacokinetic | Reduced bupivacaine metabolism (minimal clinical effect at intrathecal doses) | Minor – Not clinically significant at spinal doses |
Major Interactions
The most critical interactions that require absolute attention are those involving anticoagulant and antiplatelet therapy. The American Society of Regional Anesthesia (ASRA) and the European Society of Regional Anaesthesia (ESRA) have published comprehensive, evidence-based guidelines specifying the minimum time intervals that must be observed between the last dose of various anticoagulants and the performance of neuraxial procedures. For example, prophylactic low-molecular-weight heparin should be discontinued at least 12 hours before spinal anesthesia, while therapeutic doses require at least 24 hours. Direct oral anticoagulants such as rivaroxaban and apixaban typically require at least 72 hours of discontinuation (longer if renal function is impaired). Clopidogrel should be discontinued for at least 5–7 days, and ticagrelor for at least 5 days. These timing intervals are critical for patient safety, and any deviation must be justified by a careful risk-benefit analysis.
Another important major interaction involves the concomitant use of other local anesthetics. While intrathecal bupivacaine doses are small, if a patient has recently received or will receive large-volume local anesthetic infiltration (for example, for wound infiltration or peripheral nerve blocks), the total cumulative local anesthetic dose must be calculated to avoid exceeding toxic thresholds. Maximum safe doses of local anesthetics are cumulative when given in proximity.
Minor Interactions
Several medications produce minor or readily manageable interactions when used alongside intrathecal bupivacaine. Beta-blockers may blunt the compensatory tachycardia that normally helps maintain blood pressure during spinal-induced sympathectomy, potentially worsening hypotension. However, this interaction is easily managed with appropriate vasopressor choice (for example, using an alpha-agonist such as phenylephrine rather than a mixed agonist such as ephedrine). ACE inhibitors and angiotensin receptor blockers may impair the renin-angiotensin response to hypotension; some anesthesiologists recommend holding these medications on the morning of surgery, particularly for major procedures. Chronic use of selective serotonin reuptake inhibitors (SSRIs) does not represent a significant interaction with intrathecal bupivacaine. Herbal supplements with anticoagulant or antiplatelet effects (ginkgo biloba, garlic, ginseng, fish oil, vitamin E at high doses) should be disclosed and may need to be discontinued before surgery. These interactions are generally manageable with appropriate pre-operative planning and perioperative management.
What Is the Correct Dosage of Pankaine Spinal Tung?
Pankaine Spinal Tung is exclusively administered by qualified anesthesiologists in hospital operating theaters or procedure rooms. The dose is never standardized but rather individually tailored to each patient and each surgical procedure. Several factors influence the dose selection, including the type and expected duration of surgery, the required dermatomal level of block (that is, how high up the body the anesthesia needs to extend), the patient's age, height, weight, physical status classification, and any coexisting medical conditions. The anesthesiologist draws the required volume from the ampoule using sterile technique and injects it into the intrathecal space through a fine-gauge spinal needle, typically at the L3–L4 or L4–L5 intervertebral space (below the termination of the spinal cord, which ends at approximately L1–L2 in adults).
The injection is performed with the patient either sitting or lying on their side, depending on the intended block level and the anesthesiologist's preference. After injection, the patient's position is adjusted to allow the hyperbaric solution to reach the desired dermatomal level. For example, for a saddle block (limited to sacral dermatomes), the patient remains sitting for several minutes after injection. For a higher block suitable for cesarean section or upper abdominal surgery, the patient is placed supine or head-down. The onset of block is typically assessed by testing sensation to cold (ethyl chloride spray or ice) and pinprick to confirm adequate block level before surgery begins.
Adults
Standard Adult Dosage Ranges
The following are general dosage guidelines. Actual doses are always individually determined by the anesthesiologist based on procedural requirements and patient characteristics.
| Procedure Type | Typical Dose | Volume (5 mg/ml) | Expected Block Level | Duration |
|---|---|---|---|---|
| Perineal/saddle block | 5–7.5 mg | 1–1.5 ml | S1–L5 (sacral) | 1–2 hours |
| Lower limb surgery (knee, ankle, foot) | 10–15 mg | 2–3 ml | T10–T12 | 2–3 hours |
| Hip surgery | 12.5–17.5 mg | 2.5–3.5 ml | T8–T10 | 2–3.5 hours |
| Cesarean section | 10–12.5 mg | 2–2.5 ml | T4–T6 | 1.5–2.5 hours |
| Lower abdominal surgery | 15–20 mg | 3–4 ml | T6–T8 | 2.5–3.5 hours |
| Transurethral procedures (TURP, TURBT) | 7.5–12.5 mg | 1.5–2.5 ml | T10–T12 | 1.5–2.5 hours |
For cesarean section, the dose of Pankaine Spinal Tung is frequently combined with intrathecal adjuvants such as fentanyl (10–25 micrograms) or preservative-free morphine (100–200 micrograms) to improve the quality of intraoperative anesthesia and provide prolonged postoperative analgesia. The addition of intrathecal opioids allows a lower dose of bupivacaine to be used, which can reduce the severity of hypotension while maintaining adequate surgical anesthesia. Morphine added to the spinal injection can provide 12–24 hours of postoperative pain relief, significantly reducing the need for systemic opioids in the early postoperative period.
Children
Spinal anesthesia with bupivacaine is used in pediatric patients, although less commonly than in adults. It is particularly valuable in neonates and infants undergoing lower abdominal or lower extremity surgery, where it avoids the risks associated with general anesthesia, particularly in ex-premature infants at risk of postoperative apnea. Awake spinal anesthesia is a well-established technique for procedures such as inguinal hernia repair, orchidopexy, and lower limb surgery in this vulnerable population. Dosage in children is weight-based and varies by age group:
- Neonates and infants (< 5 kg): 0.4–0.5 mg/kg (0.08–0.1 ml/kg of the 5 mg/ml solution)
- Infants (5–15 kg): 0.3–0.4 mg/kg (0.06–0.08 ml/kg)
- Children (> 15 kg): 0.2–0.3 mg/kg (0.04–0.06 ml/kg), up to the adult dose
Pediatric spinal anesthesia requires specialized training, specific equipment (including shorter, smaller-gauge spinal needles), and specific considerations because pediatric pharmacokinetics differ significantly from adults. Children have a larger CSF volume relative to body weight, higher cardiac output resulting in faster systemic absorption, and shorter duration of block. Additionally, some children may require light sedation or parental presence to achieve cooperation for the spinal injection. These procedures should only be performed by anesthesiologists experienced in pediatric regional anesthesia, typically in centers with dedicated pediatric anesthesia services.
Elderly
Elderly patients generally require reduced doses of intrathecal Pankaine Spinal Tung compared with younger adults. This is due to several age-related physiological changes: decreased volume of cerebrospinal fluid (allowing a given dose to reach a higher dermatomal level), reduced cross-sectional area of the spinal canal due to degenerative changes, increased sensitivity to the cardiovascular effects of sympathetic blockade, slower recovery from hemodynamic changes, and slower metabolism and elimination of the drug. Dose reductions of 20–40% are commonly recommended in patients over 70 years of age. For example, a typical dose for a lower limb procedure in an elderly patient might be 7.5–10 mg rather than the 10–15 mg used in a younger adult. Careful titration, attentive hemodynamic monitoring, judicious fluid administration, and readiness to treat hypotension with vasopressors are essential components of safe anesthetic care in this population.
Missed Dose
The concept of a missed dose does not apply to Pankaine Spinal Tung, as it is a single-injection medication administered by the anesthesiologist at the time of surgery. It is not a medication that patients take at home on a regular schedule, and there is no “follow-up dose” in the usual sense. If a spinal block fails to achieve adequate surgical anesthesia, the anesthesiologist may supplement with additional medication (such as intravenous analgesia or sedation) or convert to general anesthesia, rather than attempting a repeat spinal injection within a short time frame.
Overdose
Overdose of intrathecal bupivacaine is a serious and potentially life-threatening situation that most commonly manifests as an excessively high or total spinal block rather than as classical systemic local anesthetic toxicity. Symptoms of a high spinal block include progressive numbness and weakness extending above the intended level, tingling or numbness in the fingers and arms, difficulty breathing (due to paralysis of the intercostal muscles and, in severe cases, the diaphragm), severe hypotension, profound bradycardia, nausea, and loss of consciousness. In the most severe cases (total spinal block), complete respiratory arrest and cardiovascular collapse can occur within minutes of the injection.
Treatment of intrathecal bupivacaine overdose is supportive and symptomatic, with the goal of maintaining oxygenation and circulation until the block recedes. Immediate management includes securing the airway with endotracheal intubation and providing mechanical ventilation, aggressive intravenous fluid administration, and vasopressor support (typically ephedrine, phenylephrine, or epinephrine/adrenaline depending on the clinical picture) to maintain blood pressure. Atropine or glycopyrrolate is used to treat bradycardia. The effects of the high block will gradually resolve as the local anesthetic is absorbed from the CSF and metabolized, typically over 2–4 hours. In the extremely rare event of systemic bupivacaine toxicity (which may occur if inadvertent intravascular injection has taken place), intravenous lipid emulsion (Intralipid 20%) therapy should be administered according to established protocols, as lipid rescue has been shown to be effective in reversing bupivacaine cardiotoxicity.
Pankaine Spinal Tung is never self-administered by patients. It is exclusively given by qualified anesthesiologists in controlled medical settings with full monitoring and resuscitation capability. The dose is individually calculated for each patient and each procedure based on multiple clinical factors. Patients do not need to remember or manage dosing — this is entirely the responsibility of the anesthetic team. If you have questions about your anesthetic plan, discuss them with your anesthesiologist during your pre-operative consultation.
What Are the Side Effects of Pankaine Spinal Tung?
Side effects of spinal anesthesia with Pankaine Spinal Tung can be broadly categorized into those directly caused by the pharmacological action of the drug (sympathetic blockade and nerve block effects) and those related to the spinal injection procedure itself (mechanical effects, CSF leak, infection risk). Most side effects are transient and resolve completely as the block wears off and over the following days to weeks. Your anesthesiologist will actively monitor you throughout the procedure and in the immediate postoperative period to detect and treat any adverse effects promptly.
It is important to understand that many of the “side effects” listed below are predictable physiological consequences of spinal blockade rather than unexpected adverse reactions. For example, some degree of hypotension occurs in the majority of patients receiving spinal anesthesia and is anticipated, monitored, and treated as part of routine anesthetic management. Similarly, mild numbness and weakness in the legs after surgery is expected and resolves as the block wears off over several hours.
Very Common (affects more than 1 in 10 patients)
Frequency: > 10%
- Hypotension (low blood pressure) – occurs in 20–40% of patients due to sympathetic nerve blockade causing vasodilation; may be more pronounced in pregnancy, elderly patients, and those with hypovolemia
- Nausea – often secondary to hypotension or vagal stimulation; occurs in approximately 15–25% of patients
- Bradycardia (slow heart rate) – due to blockade of cardiac sympathetic fibers (T1–T4) and the Bezold-Jarisch reflex from reduced venous return
Common (affects 1 in 10 to 1 in 100 patients)
Frequency: 1–10%
- Post-dural puncture headache (PDPH) – positional headache worsened by sitting or standing and relieved by lying flat, caused by CSF leakage through the dural puncture site
- Urinary retention – due to blockade of sacral parasympathetic nerves controlling bladder function; may require temporary bladder catheterization
- Vomiting – related to hypotension, vagal stimulation, or intrathecal opioid co-administration
- Back pain at the injection site – usually mild and self-limiting, lasting 1–3 days
- Pruritus (itching) – particularly when intrathecal opioids such as morphine are co-administered
- Shivering – related to thermoregulatory changes from sympathetic blockade
Uncommon (affects 1 in 100 to 1 in 1,000 patients)
Frequency: 0.1–1%
- Transient neurological symptoms (TNS) – pain or dysesthesia in the buttocks and legs lasting up to several days after block resolution (less common with bupivacaine than with lidocaine)
- Prolonged motor block – motor weakness lasting longer than expected, usually resolving within 24 hours
- Hearing changes – transient decrease in hearing acuity or tinnitus related to CSF pressure changes
- Paresthesia during injection – transient electric shock-like sensation during needle insertion, usually harmless
- Failed or patchy block – inadequate anesthesia requiring supplementation or conversion to general anesthesia
Rare (affects fewer than 1 in 1,000 patients)
Frequency: < 0.1%
- Total spinal block – excessive cephalad spread causing respiratory paralysis and cardiovascular collapse; requires immediate airway management and cardiovascular support
- Spinal hematoma – bleeding in the spinal canal that can compress the spinal cord (risk greatly increased with anticoagulation); symptoms include progressive back pain, leg weakness, and bladder/bowel dysfunction
- Meningitis or epidural abscess – infection of the meninges or epidural space
- Cauda equina syndrome – damage to the nerve roots of the lower spinal cord with saddle anesthesia, leg weakness, and bladder/bowel dysfunction
- Arachnoiditis – inflammation of the arachnoid membrane surrounding the spinal cord
- Anterior spinal artery syndrome – ischemia of the anterior spinal cord
- Cardiac arrest – very rare, associated with very high or total spinal block; prompt resuscitation is usually successful
- Allergic reactions – true allergy to amide-type local anesthetics is extremely rare
- Seizures – from systemic local anesthetic toxicity if inadvertent intravascular injection occurs
Post-dural puncture headache (PDPH) deserves special mention as it is one of the most commonly discussed complications when consenting patients for spinal anesthesia. PDPH typically presents as a severe, bilateral, positional headache that worsens within minutes of sitting or standing up and improves substantially when lying flat. It is often accompanied by neck stiffness, photophobia, tinnitus, or nausea. PDPH usually develops within 24–48 hours after the procedure and in most cases resolves spontaneously within one to two weeks. Risk factors include younger age (particularly patients in their twenties), female sex, pregnancy, low body mass index, and the use of larger-gauge cutting-tip (Quincke) spinal needles. The introduction of small-gauge pencil-point (atraumatic) needles, such as Whitacre and Sprotte designs, has significantly reduced the incidence of PDPH to approximately 1–2%. Treatment includes bed rest, adequate hydration, caffeine (orally or intravenously), simple analgesics such as paracetamol, and in persistent or severe cases, an epidural blood patch (injection of 15–20 ml of the patient's own venous blood into the epidural space to seal the dural hole), which has a success rate of approximately 70–90% after a single treatment.
After discharge following a procedure under spinal anesthesia, contact your healthcare provider or seek emergency care immediately if you experience: a severe positional headache that worsens when sitting or standing; new back pain combined with fever or with progressive weakness in the legs; loss of sensation or weakness in the legs that does not improve as expected (or that returns after initial recovery); loss of bladder or bowel control; difficulty urinating more than 8–12 hours after the procedure; signs of infection at the injection site (increasing redness, swelling, warmth, pus, or streaking); or persistent numbness or pins-and-needles sensations. Most side effects are self-limiting, but prompt medical evaluation of any concerning neurological symptoms is critical because some complications (such as spinal hematoma or epidural abscess) require urgent surgical intervention to prevent permanent damage.
How Should You Store Pankaine Spinal Tung?
Pankaine Spinal Tung is a sterile, preservative-free solution supplied in single-use glass ampoules. As a hospital-only medication, storage is managed entirely by the hospital pharmacy and the anesthetic department. Ampoules are typically stored in the anesthesia drug cabinet or in secure medication carts within the operating theater complex. The following storage conditions apply:
- Temperature: Store below 25°C (77°F) in a cool, dry place. Do not freeze. Freezing can damage the ampoule, compromise the sterility of the solution, and potentially alter the concentration if ice crystals form.
- Light protection: Store in the original carton to protect from direct light. Prolonged light exposure can degrade bupivacaine and affect its potency.
- Single use only: Each ampoule is intended for single use only on a single patient. Any unused solution remaining after the procedure must be discarded according to hospital waste disposal protocols. The solution does not contain preservatives, so microbial contamination is a significant risk if an opened ampoule is stored for later use.
- Visual inspection: Before use, the solution should be inspected visually. It should be clear and colorless with no visible particles. Do not use if the solution appears cloudy, discolored, has a brown or yellow tint, contains visible particles, or if the ampoule shows signs of damage such as cracks or chips.
- Expiration date: Do not use after the expiration date printed on the ampoule and outer packaging. The expiration date refers to the last day of that month. Expired medications should be returned to the pharmacy for appropriate disposal.
- Sterility: The outer surface of the ampoule is not sterile. When preparing the medication, the anesthesiologist or assistant must use aseptic technique, including disinfection of the ampoule neck before opening and use of a sterile filter needle to draw up the solution to prevent glass microparticles from being injected.
Patients undergoing spinal anesthesia with this medication do not need to worry about storage or handling. All preparation is performed by trained medical staff in a sterile environment immediately before administration. The medication is typically drawn up into a syringe using aseptic technique and injected within a short time frame, as the preservative-free formulation does not support prolonged storage of the drawn-up drug.
What Does Pankaine Spinal Tung Contain?
Pankaine Spinal Tung is a clear, colorless sterile solution supplied in glass ampoules. The complete composition is as follows:
Active Substance
- Bupivacaine hydrochloride: 5 mg per ml (equivalent to approximately 4.4 mg bupivacaine base per ml). Bupivacaine is an amide-type local anesthetic with a piperidine ring structure. It is the racemic mixture containing both the R(+) and S(-) enantiomers in equal proportions. The S(-) enantiomer is associated with less cardiac toxicity compared with the R(+) form, which is the rationale for the development of the purified S(-) enantiomer levobupivacaine as an alternative agent.
Excipients (Inactive Ingredients)
- Glucose (anhydrous or monohydrate): Typically 80 mg per ml (8%). This is the key excipient that makes the solution hyperbaric (heavier than CSF). Glucose is a physiological substance that is readily metabolized by the body and does not contribute to the pharmacological effects of the anesthetic beyond its role as a density-modifying agent. The glucose concentration of 80 mg/ml is the standard used in hyperbaric spinal anesthetic preparations worldwide and has been extensively validated in clinical practice.
- Sodium hydroxide and/or hydrochloric acid: Used in small quantities during manufacturing to adjust the pH of the solution to approximately 4.0–6.0. This pH range ensures stability of the bupivacaine molecule in solution and is within the acceptable range for intrathecal injection. The pH is lower than physiological (which is approximately 7.35–7.45) because local anesthetic salts are more stable in slightly acidic solution.
- Water for injections: Pharmaceutical-grade sterile water used as the solvent for the formulation, meeting all pharmacopoeial requirements for injectable products.
The solution is preservative-free, which is absolutely essential for intrathecal use. Preservatives such as methylparaben, propylparaben, or benzyl alcohol, which are found in some multi-dose local anesthetic formulations intended for other routes of administration (such as dental or infiltration use), are neurotoxic and must never be injected intrathecally. Even small amounts of these preservatives in the subarachnoid space can cause chemical arachnoiditis, cauda equina syndrome, or other serious neurological injury. The preservative-free nature of Pankaine Spinal Tung ensures that it is safe for injection into the subarachnoid space. This is why each ampoule is single-use only — once opened, the sterility can no longer be guaranteed without preservatives.
The specific gravity of the finished solution is approximately 1.026 at 37°C, which is significantly higher than the specific gravity of human CSF (approximately 1.003–1.009 at the same temperature). This density difference is what classifies the solution as “hyperbaric” and is the physical basis for the gravitational control of block spread that makes this formulation particularly useful in clinical anesthesia practice. The pH of the solution is approximately 4.5–6.0, and it is isotonic or slightly hypertonic compared with CSF, further supporting predictable distribution within the subarachnoid space.
Frequently Asked Questions
Pankaine Spinal Tung is a hyperbaric local anesthetic solution used for spinal (intrathecal) anesthesia during surgical procedures. It is commonly used for operations on the lower abdomen, pelvis, and lower extremities, including cesarean sections, orthopedic surgery (hip and knee replacements), urological procedures such as transurethral resection of the prostate, and hernia repairs. The hyperbaric formulation allows anesthesiologists to precisely control the extent and level of the nerve block using patient positioning on the operating table.
The duration of spinal anesthesia with Pankaine Spinal Tung typically ranges from 1.5 to 3.5 hours depending on the dose administered, with lower doses producing shorter blocks. Sensory block onset occurs within 1–5 minutes of injection, with peak surgical anesthesia reached in 10–15 minutes. A standard adult dose of 10–15 mg (2–3 ml) provides adequate surgical anesthesia for most lower body procedures. Motor block recovery is generally complete within 3–4 hours after injection. The addition of intrathecal adjuvants such as fentanyl, morphine, or clonidine can extend the duration of analgesia beyond the duration of the sensory block.
Yes, spinal anesthesia with Pankaine Spinal Tung numbs the lower body while you remain conscious and breathing normally. You will not feel pain in the surgical area but may feel pressure, pulling, or tugging sensations. If you feel anxious about being awake, your anesthesiologist can provide light to moderate sedation through an intravenous drip to help you relax, and some patients may sleep lightly through the procedure. A screen is typically placed across your chest so that you cannot see the surgical field. In certain situations — such as patient preference, very long procedures, or unexpected surgical complications — spinal anesthesia may be supplemented with or converted to general anesthesia.
Most patients describe the spinal injection as causing brief discomfort rather than significant pain. Your anesthesiologist will first numb the skin and deeper tissues at the injection site with a small injection of local anesthetic, which causes a brief stinging sensation similar to a bee sting or insect bite. The spinal needle itself is very thin (typically 25–27 gauge) and is usually felt as pressure rather than sharp pain. Some patients may feel a brief electric shock-like sensation if the needle touches a nerve root, which is transient and not harmful. The entire procedure typically takes 5–10 minutes from start to finish, and a sensation of warmth and numbness in the legs usually begins within 1–5 minutes after the injection.
Yes. Hyperbaric bupivacaine formulations such as Pankaine Spinal Tung are among the most commonly used agents for spinal anesthesia in cesarean delivery worldwide. A typical dose of 10–12.5 mg (2–2.5 ml of the 5 mg/ml solution) is usually combined with an intrathecal opioid such as fentanyl 15–25 micrograms or preservative-free morphine 100–200 micrograms to improve the quality of anesthesia and provide postoperative pain relief for 12–24 hours. The hyperbaric formulation is preferred because it provides a rapid, reliable, and predictable block level, typically reaching T4–T6. Spinal anesthesia for cesarean section is generally considered safer than general anesthesia for both mother and baby, avoiding the risks of aspiration, difficult intubation, and neonatal respiratory depression from general anesthetic agents.
Pankaine Spinal Tung contains the same active ingredient (bupivacaine hydrochloride 5 mg/ml) as other hyperbaric bupivacaine spinal products such as Marcaine Spinal Heavy, Bupivacaine Spinal Tung Aguettant, and Bupivacaine Spinal Tung Grindeks. All are hyperbaric formulations with glucose added to enable gravitational control of block spread. Clinical effects, dosing ranges, indications, contraindications, and side effect profiles are essentially identical. Differences between products are limited to inactive ingredients, ampoule design and volume, manufacturer, country of marketing authorization, and price. Regulatory authorities require all products to meet the same pharmacopoeial standards for purity, potency, and sterility.
All information is based on international medical guidelines and peer-reviewed research: the European Medicines Agency (EMA) Summary of Product Characteristics for bupivacaine, the WHO Model List of Essential Medicines, the ASRA Fourth Edition Guidelines on Neuraxial Anesthesia and Anticoagulation (2018), ESRA Guidelines on Neuraxial Blocks, Cochrane systematic reviews of spinal anesthesia techniques, and peer-reviewed publications in leading anesthesia journals including Anaesthesia, Regional Anesthesia and Pain Medicine, British Journal of Anaesthesia, and Anesthesiology. All medical claims follow the GRADE evidence framework with the highest quality of evidence based on systematic reviews and randomized controlled trials. Content is reviewed by board-certified anesthesiologists before publication.
References
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023. Bupivacaine listed as an essential local anesthetic for infiltration and spinal anesthesia.
- European Medicines Agency (EMA). Bupivacaine hydrochloride – Summary of Product Characteristics. EMA product database. Accessed January 2026.
- Horlocker TT, Vandermeuelen E, Kopp SL, et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med. 2018;43(3):263–309.
- Gogarten W, Vandermeulen E, Van Aken H, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27(12):999–1015.
- Arzola C, Wieczorek PM. Efficacy of low-dose bupivacaine in spinal anaesthesia for Caesarean delivery: systematic review and meta-analysis. Br J Anaesth. 2011;107(3):308–318.
- Ngan Kee WD, Khaw KS, Ng FF. Comparison of phenylephrine infusion regimens for maintaining maternal blood pressure during spinal anaesthesia for Caesarean section. Br J Anaesth. 2004;92(4):469–474.
- Hocking G, Wildsmith JAW. Intrathecal drug spread. Br J Anaesth. 2004;93(4):568–578.
- Lim Y, Sia AT, Tan AK. Comparison of hyperbaric and isobaric bupivacaine for spinal anaesthesia. Anesth Analg. 2004;98(3):642–646.
- Neal JM, Barrington MJ, Fettiplace MR, et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity. Reg Anesth Pain Med. 2018;43(2):113–123.
- Sng BL, Han NLR, Leong WL, et al. Hyperbaric vs. isobaric bupivacaine for spinal anaesthesia for elective caesarean section: a Cochrane systematic review. Anaesthesia. 2018;73(4):499–511.
- Bernards CM, Hostetter LS. Epidural and Spinal Anesthesia. In: Barash PG, ed. Clinical Anesthesia. 8th ed. Wolters Kluwer; 2017.
- Cowan CM. Spinal Anaesthesia. Anaesth Intensive Care Med. 2022;23(10):583–588.
Medical Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Anesthesiology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent expert review according to international guidelines (WHO, EMA, ESRA, ASRA)
Evidence Standard
Level 1A – Based on systematic reviews and meta-analyses of randomized controlled trials, following the GRADE evidence framework
Editorial Independence
No commercial funding or pharmaceutical sponsorship. All content is editorially independent and free from conflicts of interest.
Published: | Last reviewed: | Next review: